Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olav Dalgard

Showing results (61-70 of 107) with videos related to

Pageof 11
Sort By:
Plos One|May 12, 2016
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 InfectionJesper Waldenström, Johan Westin, Kristina Nyström, et al.
Journal of Hepatology|December 1, 2019
Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysisBehzad Hajarizadeh, Evan B Cunningham, Heather Valerio, et al.
Journal of Viral Hepatitis|May 18, 2021
Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and CErika Duffell, Helena Cortez-Pinto, Marieta Simonova, et al.
Hepatology (Baltimore, Md.)|November 3, 2007
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological responseOlav Dalgard, Kristian Bjøro, Helmer Ring-Larsen, et al.
European Journal of Immunology|November 23, 2011
CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patientsVivien Béziat, Olav Dalgard, Tarik Asselah, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 22, 2023
Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized TrialHåvard Midgard, Kristian Braathen Malme, Charlotte Meinich Pihl, et al.
Journal of Addictive Diseases|March 31, 2022
Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrationsFatemeh Chalabianloo, Gudrun Høiseth, Jørn Henrik Vold, et al.
Scandinavian Journal of Gastroenterology|September 5, 2022
High real-world effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in NorwayRafael A Leiva, Bente M Bergersen, Ane-Kristine Finbråten, et al.
Drug and Alcohol Review|October 26, 2025
Changes in Risk Behaviour Among People With Recent Injecting Drug Use in Oslo 2002-2024Eirik Opheim, Kristian Malme, Olav Dalgard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 26, 2013
Recommendations for the management of hepatitis C virus infection among people who inject drugsGeert Robaeys, Jason Grebely, Stefan Mauss, et al.
Pageof 11

Showing results (61-70 of 107) with videos related to

Sort By:
Pageof 11
Plos One|May 12, 2016
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 InfectionJesper Waldenström, Johan Westin, Kristina Nyström, et al.
Journal of Hepatology|December 1, 2019
Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysisBehzad Hajarizadeh, Evan B Cunningham, Heather Valerio, et al.
Journal of Viral Hepatitis|May 18, 2021
Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and CErika Duffell, Helena Cortez-Pinto, Marieta Simonova, et al.
Hepatology (Baltimore, Md.)|November 3, 2007
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological responseOlav Dalgard, Kristian Bjøro, Helmer Ring-Larsen, et al.
European Journal of Immunology|November 23, 2011
CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patientsVivien Béziat, Olav Dalgard, Tarik Asselah, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 22, 2023
Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized TrialHåvard Midgard, Kristian Braathen Malme, Charlotte Meinich Pihl, et al.
Journal of Addictive Diseases|March 31, 2022
Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrationsFatemeh Chalabianloo, Gudrun Høiseth, Jørn Henrik Vold, et al.
Scandinavian Journal of Gastroenterology|September 5, 2022
High real-world effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in NorwayRafael A Leiva, Bente M Bergersen, Ane-Kristine Finbråten, et al.
Drug and Alcohol Review|October 26, 2025
Changes in Risk Behaviour Among People With Recent Injecting Drug Use in Oslo 2002-2024Eirik Opheim, Kristian Malme, Olav Dalgard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 26, 2013
Recommendations for the management of hepatitis C virus infection among people who inject drugsGeert Robaeys, Jason Grebely, Stefan Mauss, et al.
Pageof 11